Adam D. Levy

CIK: 0002061876

Transaction Breakdown

Open Market Buys (P)1 (16.7%)

High conviction signal

Open Market Sales (S)1 (16.7%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (16.7%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ACRV

Acrivon Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (6 total)

ACRV
Acrivon Therapeutics, Inc.
Aug 4, 2026
Sale(S)
Direct
1.1K shares at avg. $1.57$2K
ACRV
Acrivon Therapeutics, Inc.
May 18, 2026
Award(A)
Direct
46.2K shares-
ACRV
Acrivon Therapeutics, Inc.
Mar 1, 2026
Award(A)
Stock Option (Right to Buy)
Direct
132.9K shares-
ACRV
Acrivon Therapeutics, Inc.
Jan 14, 2026
Purchase(P)
Direct
8.8K shares at avg. $1.70$15K
ACRV
Acrivon Therapeutics, Inc.
Aug 1, 2025
Tax Payment(F)
Direct
1.2K shares at avg. $1.26$1K
ACRV
Acrivon Therapeutics, Inc.
Apr 1, 2025
Award(A)
Stock Option (Right to Buy)
Direct
35.2K shares-

		Type	Shares	Price		Ownership
Aug 4, 2026	ACRV Acrivon Therapeutics, Inc.	Sale(S)	1,142	$1.57	$1,793	Direct
May 18, 2026	ACRV Acrivon Therapeutics, Inc.	Award(A)	46,167	-	$0	Direct
Mar 1, 2026	ACRV Acrivon Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	132,925	-	-	Direct
Jan 14, 2026	ACRV Acrivon Therapeutics, Inc.	Purchase(P)	8,832	$1.70	$14,999	Direct
Aug 1, 2025	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	1,164	$1.26	$1,467	Direct
Apr 1, 2025	ACRV Acrivon Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	35,209	-	-	Direct

1-6 of 6 transactions

About Levy Adam D.

Levy Adam D. (SEC CIK 0002061876) files insider reports with the SEC as Chief Financial Officer of Acrivon Therapeutics, Inc. (ACRV).

Signal8 holds 7 ownership filings by Levy Adam D. (1 Form 3, 6 Form 4), filed between Apr 3, 2025 and Aug 6, 2026. Those filings report 6 transactions, from Apr 1, 2025 to Aug 4, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Levy Adam D.'s filings is in WATERTOWN, MA.

Recent filings by Levy Adam D.

Aug 4, 2026: Open-market sale of ACRV shares (Form 4, code S).
May 18, 2026: Grant or award of ACRV shares (Form 4, code A).
Mar 1, 2026: Grant or award of ACRV derivative securities (Form 4, code A).
Jan 14, 2026: Open-market purchase of ACRV shares (Form 4, code P).
Aug 1, 2025: Tax withholding of ACRV shares (Form 4, code F).

Other insiders filing for Acrivon Therapeutics, Inc. (ACRV)

Miller Mary, Chief Legal Officer
Levin Michaela, Chief Business Officer
Blume-Jensen Peter, President and CEO
Peterson Katharine, Chief Accounting Officer
Gamelin Erick, Chief Development Officer
Devroe Eric, Chief Operating Officer

How to read Form 4 transaction codes